Teacher Retirement System of Texas Has $579,000 Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Teacher Retirement System of Texas raised its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 31.9% in the fourth quarter, HoldingsChannel reports. The fund owned 22,536 shares of the company’s stock after purchasing an additional 5,451 shares during the quarter. Teacher Retirement System of Texas’ holdings in IDEAYA Biosciences were worth $579,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at $35,000. Daiwa Securities Group Inc. lifted its stake in shares of IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after buying an additional 853 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of IDEAYA Biosciences during the third quarter valued at about $83,000. KBC Group NV increased its position in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter worth about $203,000. Institutional investors own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

IDYA has been the subject of a number of analyst reports. Stephens reiterated an “overweight” rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Wedbush reiterated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Stock Down 2.2 %

IDYA opened at $17.05 on Monday. IDEAYA Biosciences, Inc. has a twelve month low of $16.88 and a twelve month high of $44.42. The company’s 50-day moving average price is $20.80 and its two-hundred day moving average price is $25.77. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -5.17 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.